National Resilience acquired the Triangle office in 2021. Since then, funding for gene therapy solutions has fallen.

XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

One drive is the rising prevalence of chronic diseases like cancer and diabetes. Increased investment in research and development is accelerating the discovery and refinement of cell and gene ...

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody ...